SCHEMBL13325

SCHEMBL13325

CNS(=O)(=O)Cc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.63
CA2 P00918 2/20 0.63
MMP1 P03956 1/20 0.63
MMP2 P08253 1/20 0.63
MMP9 P14780 1/20 0.63
MMP8 P22894 1/20 0.63
MMP13 P45452 1/20 0.63
FAAH O00519 1/20 0.52
PRSS1 P07477 1/20 0.52
PRSS2 P07478 1/20 0.52
ELANE P08246 1/20 0.52
PRTN3 P24158 1/20 0.52
PRSS3 P35030 1/20 0.52
CA5A P35218 1/20 0.52
CA9 Q16790 1/20 0.52
KMT2A Q03164 2/20 0.52
ALDH1A1 P00352 5/20 0.51
HPGD P15428 4/20 0.51
KDM4E B2RXH2 3/20 0.51
MEN1 O00255 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11516753 0.98 CA1 (0.61) CA1CA2MMP1MMP2MMP9
Hydrochloric Acid SCHEMBL7559872 0.98 CA1 (0.61) CA1CA2MMP1MMP2MMP9
SCHEMBL6492175 0.81 CA1 (0.68) CA1CA2MMP1MMP2MMP9
SCHEMBL8261072 0.80 HPGD (0.48) CA1CA2MMP1MMP2MMP9
SCHEMBL9046172 0.80 GAA (0.48) CA1CA2MMP1MMP2MMP9
SCHEMBL634963 0.80 CA1 (0.61) CA1CA2MMP1MMP2MMP9
SCHEMBL465380 0.79 CA1 (0.65) CA1CA2MMP1MMP2MMP9
SCHEMBL21763639 0.79 CA1 (0.65) CA1CA2MMP1MMP2MMP9
SCHEMBL9006011 0.79 CA1 (0.65) CA1CA2MMP1MMP2MMP9
SCHEMBL24361302 0.78 CA1 (0.59) CA1CA2MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119233829-A Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy 学校法人高崎健康福祉大学 2024-12-31 CN claimed
EP-4408432-A1 MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN Nippon Chemiphar Co., Ltd. (JP) 2024-08-07 EP claimed
CN-118176003-A Medicaments comprising P2X4 receptor antagonists for the prevention or treatment of nociceptive pain and/or visceral pain 日本化学药品株式会社 2024-06-11 CN claimed
CN-118019551-A Preventive or therapeutic agent for respiratory diseases 日本化学药品株式会社 2024-05-10 CN claimed
US-11666582-B2 Medicament for treating cough NIPPON CHEMIPHAR CO., LTD. (JP) 2023-06-06 US claimed
CN-115942938-A Medicine for preventing or treating irritable bowel syndrome or inflammatory bowel disease 比萨大学 2023-04-07 CN claimed
WO-2023052518-A1 MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) 2023-04-06 WO claimed
CN-111606829-B Production method of o-methyl formate benzyl sulfonamide 淄博腾煜化工工程有限公司 2022-07-08 CN claimed
CN-109337282-B High-thermal-stability polyformaldehyde resin and preparation method thereof 万华化学集团股份有限公司 2021-03-09 CN claimed
CN-111606829-A Production method of o-methyl formate benzyl sulfonamide 淄博腾煜化工工程有限公司 2020-09-01 CN claimed
EP-1521746-A1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X-Ceptor Therapeutics, Inc. (US) 2005-04-13 EP claimed
US-20040225006-A1 (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates SMITHKLINE BEECHAM P.L.C. 2004-11-11 US claimed
US-20030199571-A1 (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives SMITHKLINE BEECHAM P.L.C. (GB) 2003-10-23 US claimed
WO-2003076418-A1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X-CEPTOR THERAPEUTICS, INC. (US) 2003-09-18 WO claimed
EP-1244616-A1 (HETERO)BICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES SmithKline Beecham plc (GB) 2002-10-02 EP claimed
WO-2001047874-A1 (HETERO)BICYCLYMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES SMITHKLINE BEECHAM P.L.C. (GB) 2001-07-05 WO claimed
EP-0468470-B1 Benzimidazoles, medicaments containing them and process for their preparation THOMAE GMBH DR K (DE) 1997-04-16 EP claimed
US-20250360143-A1 COMPOSITIONS AND METHODS FOR PHARMACOLOGIC TREATMENT OF STROKE AND MYOCARDIAL ISCHEMIA REPERFUSION INJURY UNIV CONNECTICUT (US) 2025-11-27 US disclosed
EP-0192106-A1 Sulphone derivatives, their preparation and their use CASSELLA Aktiengesellschaft (DE) 1986-08-27 EP disclosed
US-3987040-A 3-SUBSTITUTED METHYL-7-ACYLAMINO-7-METHOXY-2-CEPHEM-4-CARBOXYLIC ACID AND ITS ESTERS MERCK & CO., INC. (US) 1976-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250360143-A1 COMPOSITIONS AND METHODS FOR PHARMACOLOGIC TREATMENT OF STROKE AND MYOCARDIAL ISCHEMIA REPERFUSION INJURY PLAT, SERPINE1, SERPINC1 CA1 419/4885CA2 1428/4885MMP1 59/4885
US-11666582-B2 Medicament for treating cough P2RX4, P2RX3, P2RX5 CA1 1586/4885CA2 92/4885MMP1 2665/4885
US-20030199571-A1 (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives CD40, CD22, CD2 CA1 189/4885CA2 673/4885MMP1 1030/4885
US-20040225006-A1 (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates CD40, TNFRSF1A, CD2 CA1 219/4885CA2 1138/4885MMP1 559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.